Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
490.97
+3.60 (+0.74%)
Streaming Delayed Price
Updated: 9:57 AM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest
April 25, 2024
Via
Benzinga
2 Fantastic Growth Stocks to Buy Right Now
April 25, 2024
Don't overlook these high-growth businesses.
Via
The Motley Fool
Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.
April 24, 2024
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
Via
The Motley Fool
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
April 23, 2024
Vertex is broadening its portfolio.
Via
The Motley Fool
Making Sense of Amazon CEO Andy Jassy's Latest Letter
April 22, 2024
And that's just part of the interesting news for investors to dig into.
Via
The Motley Fool
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today
April 16, 2024
Via
Benzinga
The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals
April 12, 2024
Via
Benzinga
Vertex Pharmaceuticals: Buy, Sell, or Hold?
April 11, 2024
The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?
Via
The Motley Fool
If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today
April 22, 2024
Could Vertex's growth story continue?
Via
The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
April 22, 2024
These stocks could be near major inflection points.
Via
The Motley Fool
2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever
April 20, 2024
These stocks probably won't be getting much cheaper.
Via
The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
April 20, 2024
Low risk and high-reward potential? These stocks could offer both.
Via
The Motley Fool
3 Biotech Stocks Set to Double by 2028
April 20, 2024
These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains.
Via
InvestorPlace
Is Vertex Pharmaceuticals Stock a Millionaire Maker?
April 19, 2024
Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more?
Via
The Motley Fool
Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday
April 18, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
April 18, 2024
The biotech just added another potential growth driver to its pipeline.
Via
The Motley Fool
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
April 18, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
April 15, 2024
Vertex just laid claim to an asset that might be very valuable.
Via
The Motley Fool
Could This Stock Be the Next Biotech Buyout?
April 13, 2024
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Via
The Motley Fool
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...
Via
Benzinga
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
April 11, 2024
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
April 11, 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
Via
InvestorPlace
Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock
April 11, 2024
Nvidia stock is on the move Thursday after shares of NVDA got an increased price target of $1,100 from Raymond James analysts.
Via
InvestorPlace
Apple Spyware Warning: What to Know About ‘Mercenary Spyware Attack’ Alerts
April 11, 2024
An Apple spyware warning has been sent to iPhone owners in 92 states as they have been targeted by a mercenary spyware attack.
Via
InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Via
Investor's Business Daily
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to...
Via
Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
April 11, 2024
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
April 10, 2024
The companies expect the deal to close later this quarter.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.